If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
Description
Anti-Human CD20 Therapeutic Antibody (Zevalin). Recombinant monoclonal antibody to Human CD20. Ibritumomab tiuxetan, sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma, a lymphoproliferative disorder and thus affects the lymphatic system. The drug uses the monoclonal mouse IgG1 antibody ibritumomab (pronounced as ) in conjunction with the chelator tiuxetan, to which a radioactive isotope (either yttrium-90 or indium-111) is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl groupSuitable for use in ELISA, western blot, immunohistochemistry, flow cytometry, immunoaffinity purification and most other immunological methods. ELISA, IP, FC, FuncS, IF, Neut and most other immunological methods.
Immunogen
Human lymphoblastoid cell line SB
Other Names
Ibritumomab;zevalin;174722-31-7;Zevalin;Ibritumomab ;DB00078MS4A1;membrane-spanning 4-domains, subfamily A, member 1;CD20;B-lymphocyte antigen CD20;B1;Bp35;MS4A2;CD20 antigen;CD20 receptor;leukocyte surface antigen Leu-16;B-lymphocyte cell-surface antigen